SCHEMBL3962219

SCHEMBL3962219

c1cn(N2CCCCC2)nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4062543 0.98
Hydrochloric Acid SCHEMBL28821719 0.98
SCHEMBL956232 0.98
Hydrochloric Acid SCHEMBL8119809 0.95
SCHEMBL27482372 0.77
SCHEMBL4804071 0.77 EGLN2 (0.30)
SCHEMBL6527341 0.77 KDM4E (0.32)
SCHEMBL3070359 0.73 NOTUM (0.33)
SCHEMBL16964981 0.67
SCHEMBL2067806 0.67 ADORA2A (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1737843-A4 INHIBITORS OF AKT ACTIVITY MERCK & CO INC (US) 2009-01-28 EP claimed
EP-1737843-A1 INHIBITORS OF AKT ACTIVITY Merck & Co., Inc. (US) 2007-01-03 EP claimed
WO-2005100344-A1 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2005-10-27 WO claimed
EP-4471029-A1 METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER Suzhou Genhouse Bio Co., Ltd. (CN) 2024-12-04 EP disclosed
US-20240391923-A1 METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER SUZHOU GENHOUSE BIO CO., LTD. (CN) 2024-11-28 US disclosed
CN-109666158-B Hybrid dynamic polymer and application thereof 厦门逍扬运动科技有限公司 2023-04-07 CN disclosed
WO-2021078227-A1 FUSED HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2021-04-29 WO disclosed
CN-109666130-A A kind of energy-absorbing method based on dynamic aggregation object 翁秋梅 2019-04-23 CN disclosed
CN-109666158-A A kind of hydridization dynamic aggregation object and its application 翁秋梅 2019-04-23 CN disclosed
CN-104650062-B A kind of nitrogenous heterocyclic thiazole and its production and use 南开大学 2018-01-19 CN disclosed
EP-1879873-B1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK BIOPHARMACEUTICALS CO LTD (KR) 2013-10-09 EP disclosed
CN-101578275-A Anilinopiperazine derivatives and methods of use thereof SCHERING CORP (US) 2009-11-11 CN disclosed
CN-101472904-A Diazepan derivatives modulators of chemokine receptors HOFFMANN LA ROCHE (CH) 2009-07-01 CN disclosed
EP-1737843-A4 INHIBITORS OF AKT ACTIVITY MERCK & CO INC (US) 2009-01-28 EP disclosed
CN-101228138-A Neurotherapeutic azole compounds SK HOLDINGS CO LTD (KR) 2008-07-23 CN disclosed
EP-1737843-A1 INHIBITORS OF AKT ACTIVITY Merck & Co., Inc. (US) 2007-01-03 EP disclosed
EP-1716143-A1 POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2006-11-02 EP disclosed
WO-2005100344-A1 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2005-10-27 WO disclosed
WO-2005080386-A1 POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (US) 2005-09-01 WO disclosed
CN-1655785-A N-acylpiperidine derivatives as melanocortin receptor ligands in the treatment of feeding disorders PROCTER & GAMBLE (US) 2005-08-17 CN disclosed